Anamorelin: A Literature Course in Six Modules

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, condition, or treatment. Nothing here describes a protocol, and no outcome is presented as achievable for any individual reader. The course below summarises what published papers on anamorelin investigated and what their authors reported.

Module 1: What Anamorelin Is and How It Has Been Studied

Anamorelin (anamorelin hydrochloride) is an orally active compound developed as an agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a), the receptor for the hormone ghrelin. Although it is often grouped with "peptides" because of its ghrelin-mimetic action, a 2018 review and expert opinion explicitly characterised anamorelin as a non-peptide ghrelin analogue rather than a peptide chain (PMID 30400622). A 2015 expert opinion on pharmacotherapy described it as an orally administered agent investigated for cancer-anorexia-cachexia in non-small-cell lung cancer (NSCLC) (PMID 25945893).

Where it came from and what it was developed for

The published development programme centred on cancer anorexia-cachexia syndrome — the involuntary loss of weight, muscle and appetite seen in advanced malignancy. A 2017 review in Future Oncology framed anamorelin hydrochloride as an emerging option in the management of patients with cancer anorexia-cachexia (PMID 28621564), and a 2017 oncology update summarised the same clinical context (PMID 28855797). A 2021 overview positioned it among treatment options for cancer-associated anorexia and cachexia (PMID 33491505), and a 2022 review in Drugs of Today covered anamorelin for cancer cachexia as a defined therapeutic entity (PMID 35274629).

Forms described in the literature

The form appearing throughout the verified literature is an oral once-daily tablet of anamorelin hydrochloride; the phase 3 programme used oral anamorelin 100 mg once daily (PMID 26906526). No injectable, nasal, or transdermal presentation is described in the sources reviewed here.

Limits of the evidence in Module 1: the verified sources define anamorelin by its clinical development in oncology. They do not describe use in healthy volunteers, athletic populations, or non-cancer weight loss, and they do not characterise research-grade powders or other unapproved formats.

Module 2: Mechanism as Described in the Literature

Ghrelin is a gut-derived hormone that signals through GHS-R1a in the hypothalamus and pituitary, where it is linked to appetite signalling and to pulsatile growth hormone release. Anamorelin was designed to reproduce that signalling with an orally bioavailable molecule; the 2018 expert review described it as a non-peptide ghrelin analogue acting at the ghrelin receptor in patients with advanced NSCLC and cachexia (PMID 30400622).

Reviews have described the intended downstream consequences in two broad arms. The first is orexigenic: increased appetite and food intake via hypothalamic ghrelin signalling, which the 2017 Future Oncology review discussed in the context of the anorexia component of cachexia (PMID 28621564). The second is anabolic: stimulation of the growth hormone/insulin-like growth factor-1 axis, described in the 2021 pharmacotherapy overview as part of the rationale for effects on body composition (PMID 33491505). The 2015 expert opinion set out the same mechanistic reasoning when explaining why a ghrelin receptor agonist was selected for cancer-anorexia-cachexia in NSCLC (PMID 25945893).

A 2017 commentary asking "what is next after anamorelin?" placed this mechanism within the wider problem of multifactorial cachexia, in which inflammation, catabolic signalling and reduced intake act together rather than through a single receptor pathway (PMID 28957883).

Limits of the evidence in Module 2: mechanism in these papers is largely inferred from receptor pharmacology and from clinical body-composition endpoints. The verified sources do not provide receptor-occupancy data, human tissue-level measurements, or a demonstration that any single mechanistic step caused any particular clinical endpoint.

Module 3: Reported Outcomes by Study

The phase 3 programme in non-small-cell lung cancer

The two randomised, double-blind, placebo-controlled phase 3 trials known as ROMANA 1 and ROMANA 2 enrolled patients with advanced NSCLC and cachexia and administered oral anamorelin 100 mg once daily or placebo for 12 weeks (PMID 26906526). The co-primary endpoints were change in lean body mass and change in handgrip strength, and researchers reported that lean body mass increased with anamorelin compared with placebo in both trials while handgrip strength did not differ significantly between groups (PMID 26906526).

Pooled analyses

A 2017 systematic review and meta-analysis of anamorelin for cancer anorexia-cachexia syndrome pooled randomised data and reported gains in lean body mass and body weight alongside anorexia-cachexia symptom measures, without a corresponding significant improvement in handgrip strength (PMID 28074289). A separate 2017 systematic review and meta-analysis restricted to advanced NSCLC with cachexia reported the same overall pattern of body-composition change without a demonstrated functional strength benefit (PMID 29191597).

Observational and post-approval experience

A 2025 observational study examined the effect of anamorelin on body weight in patients with gastric cancer-associated cachexia and reported body-weight outcomes under routine clinical use rather than under randomised conditions (PMID 40627291). A 2023 update on anamorelin in Japanese patients with cancer cachexia summarised clinical experience after national approval, including use across the tumour types covered by that approval (PMID 37389636).

Limits of the evidence in Module 3: the largest randomised dataset covers 12 weeks in one tumour type, and the study met one co-primary endpoint while missing the other. Observational data cannot separate drug effect from changes in disease course or supportive care. None of these reports establishes an outcome for any individual, and none describes results in people without cancer cachexia.

Module 4: Anamorelin Side Effects: What Studies Report

Adverse events in this literature are reported as trial-level frequencies in seriously ill oncology populations, where symptoms from the underlying cancer and from concurrent treatment overlap heavily with drug effects.

In the phase 3 NSCLC programme, researchers reported hyperglycaemia and nausea among the treatment-related adverse events recorded during 12 weeks of anamorelin 100 mg once daily versus placebo (PMID 26906526). The 2017 systematic review and meta-analysis of anamorelin for cancer anorexia-cachexia syndrome pooled safety data across randomised trials and summarised the reported adverse-event profile alongside the efficacy endpoints (PMID 28074289), and the NSCLC-specific meta-analysis similarly tabulated adverse events reported in the included trials (PMID 29191597).

Narrative reviews have repeatedly linked the tolerability discussion to the compound's activation of the growth hormone/IGF-1 axis, with glucose-metabolism effects treated as the safety signal of principal interest; the 2021 pharmacotherapy overview discussed safety in that framework (PMID 33491505), as did the 2022 Drugs of Today review of anamorelin for cancer cachexia (PMID 35274629). The 2023 update on Japanese patients described safety experience accumulated after approval in that country (PMID 37389636), and the 2018 expert review addressed tolerability when weighing the NSCLC evidence (PMID 30400622).

Limits of the evidence in Module 4: safety data come from short randomised exposure in advanced cancer plus post-approval observation in one country. Long-term safety, safety in people without cachexia, interactions with non-oncology medicines, and effects in pregnancy or in adolescents are not characterised in the verified sources. Rare events would not be detectable in trials of this size.

Module 5: Pharmacokinetics Where Data Exist

The verified literature is clinical rather than pharmacokinetic in emphasis, so what can be stated is limited. The defining pharmacokinetic property described is oral bioavailability sufficient for once-daily dosing: the phase 3 trials administered anamorelin orally at 100 mg once daily across a 12-week treatment period (PMID 26906526), and the 2015 expert opinion discussed anamorelin hydrochloride as an orally available agent for cancer-anorexia-cachexia in NSCLC (PMID 25945893). The 2018 review reiterated that the compound's non-peptide structure underlies its suitability for oral administration (PMID 30400622). The 2022 review covered its overall pharmacological profile in cancer cachexia (PMID 35274629).

Limits of the evidence in Module 5: absorption constants, half-life, protein binding, metabolic pathways, renal or hepatic adjustment, food effects, and drug-drug interaction data are not reported in the sources verified for this page, and they are therefore omitted rather than approximated.

Module 6: Regulatory Status, Stated Factually

Anamorelin's regulatory history differs sharply by jurisdiction. A 2023 update described anamorelin in Japanese patients with cancer cachexia following its national approval, making Japan the setting in which approved clinical use is documented in this literature (PMID 37389636); the 2022 Drugs of Today review also addressed anamorelin as an approved product for cancer cachexia (PMID 35274629). The 2017 commentary "What is next after anamorelin?" discussed the regulatory and developmental uncertainty that followed the phase 3 programme, particularly the mismatch between the lean-mass endpoint and the functional endpoint (PMID 28957883). None of the verified sources describes approval by the United States Food and Drug Administration.

Research-use-only material and compounding

Chemicals labelled "research use only" (RUO) are supplied for laboratory work and are not approved medicines; RUO labelling asserts that the material has not been evaluated for human administration and is not authorised for it. Separately, compounded preparations made by pharmacies are not FDA-approved products: approval applies to specific manufactured products with reviewed data on identity, purity, potency, labelling and manufacturing controls, and a compounded preparation has not passed through that review. These are general regulatory descriptions, not statements about any specific product's legality in any jurisdiction, and nothing on this page is legal advice.

Limits of the evidence in Module 6: regulatory status changes over time and by country, and the verified papers capture only the status described at their publication dates. Readers seeking current status should consult the relevant national regulator directly.

What the Studies Did Not Test

Reading the verified literature as a whole, several questions remain outside what was studied:

• Healthy populations. The trials and reviews describe patients with advanced cancer and cachexia; the sources contain no evaluation in healthy adults, recreational athletes, or people seeking body-composition change outside of disease (PMID 26906526).
• Function and survival as primary wins. Handgrip strength, one of the co-primary endpoints in the phase 3 programme, did not differ significantly from placebo (PMID 26906526), and pooled analyses did not resolve that gap (PMID 29191597).
• Long horizons. The randomised exposure summarised here is 12 weeks (PMID 26906526); multi-year safety and durability of body-composition change are not characterised.
• Comparative and combination strategies. The 2017 commentary framed multimodal approaches to cachexia as an open question rather than a settled one (PMID 28957883).
• Non-oncology cachexia. Cachexia from heart failure, COPD, renal disease or HIV is not addressed in the verified sources, which centre on cancer populations (PMID 33491505).

Anamorelin is therefore best understood from this literature as a compound with a clearly defined receptor rationale, one large randomised programme that met a body-composition endpoint but not a strength endpoint, pooled analyses that reproduced that split, and an approval confined to a single national market at the time these papers were written. Again, this page is educational only and is not medical advice; decisions about any medicine belong with a licensed physician who knows the individual case.

References

• Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials (The Lancet Oncology, 2016)
• Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis (Supportive Care in Cancer, 2017)
• Anamorelin for advanced non-small-cell lung cancer with cachexia: Systematic review and meta-analysis (Lung Cancer, 2017)
• Effect of anamorelin on body weight in patients with gastric cancer-associated cachexia: an observational study (Gastric Cancer, 2025)
• Anamorelin in Japanese patients with cancer cachexia: an update (Current Opinion in Supportive and Palliative Care, 2023)
• Anamorelin for cancer cachexia (Drugs of Today, 2022)
• An overview of anamorelin as a treatment option for cancer-associated anorexia and cachexia (Expert Opinion on Pharmacotherapy, 2021)
• Efficacy of Anamorelin, a Novel Non-Peptide Ghrelin Analogue, in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Cachexia-Review and Expert Opinion (International Journal of Molecular Sciences, 2018)
• The emerging role of anamorelin hydrochloride in the management of patients with cancer anorexia-cachexia (Future Oncology, 2017)
• Oncology Update: Anamorelin (Palliative Care, 2017)
• What is next after anamorelin? (Current Opinion in Supportive and Palliative Care, 2017)
• Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC (Expert Opinion on Pharmacotherapy, 2015)